Skip to main content
. 2023 Nov 24;57(11):12–24. doi: 10.47895/amp.vi0.4816

Figure 2.

Figure 2

Proportion of patients (%) receiving SABA prescriptions in the 12 months before study entry according to investigator-classified asthma severity and practice type in the SABINA III Philippines cohort: (A) all patients, (B) mild asthma, (C) moderate-to-severe asthma.